69 -1 (33) 2021 — Yuldasheva N. E., Karabaeva F. U., — PATHOGENESIS, DIAGNOSTICS AND TREATMENT OF ANEMIA IN VIRAL HEPATITIS AND LIVER CIRROSIS
PATHOGENESIS, DIAGNOSTICS AND TREATMENT OF ANEMIA IN VIRAL HEPATITIS AND LIVER CIRROSIS
Yuldasheva N.E. -Andijan State Medical Institute
Karabaeva F. U., -Andijan State Medical Institute
Tozhiddinov Kh. S., -Andijan State Medical Institute
Abdurakhmanov Sh. A. -Andijan State Medical Institute
Resume
In chronic liver disease, mild to moderate anemia is usually detected, which can be normochromic, macrocytic, and hypochromic with gastrointestinal bleeding. The pathogenesis of anemia in hepatitis and cirrhosis of the liver is complex and diverse.
In the development of anemia, the violation of proliferation processes and the maturation of erythroblasts in the bone marrow with the release of defective erythrocytes into the peripheral blood, as well as the toxic effect of viruses, drugs, and toxins on erythron, is important. A certain role in the development of anemia in liver cirrhosis is played by a violation of the absorption and metabolism of iron, a deficiency of folic acid and vitamin B12.
Key words: viral hepatitis, liver cirrhosis, anemia, treatment, diagnosis.
First page
358
Last page
362
For citation: Yuldasheva N. E., Karabaeva F. U., Tozhiddinov Kh. S., Abdurakhmanov Sh. A. Pathogenesis, diagnostics and treatment of anemia in viral hepatitis and liver cirrhosis//New Day in Medicine 1(33)2021 358-362 https://cutt.ly/mcovPIG
LIST OF REFERENCES
- Ambalov Yu.M., Vasilyeva I.I., Ryazanova O.A. and other Clinical and pathogenetic features of herpes simplex in different periods of the disease // Epidemiology and infectious diseases. – 2009. – No. 3. – T. 2. – S. 22-27.
- Vasilyeva II, Dontsov DV, Kuznetsova GV, Suladze AG // 61st Final Scientific. conf. young scientists: Abstracts of reports and materials of the Science Day Rostov. state honey. un-that. – Rostov-n / D, 2007 .– S. 47-48.
- Dontsov DV, Ambalov Yu. M., Alekseeva NN The role of changes in a number of indicators of the functional state of the cardiovascular system in the clinic and pathogenesis of chronic hepatitis C // Fundamental research. – 2012. – No. 2. – S. 290-293.
- Berry L., Irving W. Predictors of hepatitis C treatment response: what’s new? // Expert Review of Anti-infective Therapy. – 2014. – Vol. 12, No. 2. – P. 183-191.
- Flisiak R., Jaroszewicz J., Parfieniuk-Kowerda A. Emerging treatments for hepatitis C // Expert Opinion on Emerging Drugs. – 2013. – Vol. 18, No. 4. – P. 461-475.
- Hashemi N., Rossi S., Navarro V.J. Safety of peginterferon in the treatment of chronic hepatitis C // Expert Opinion on Drug Safety. – 2008. – Vol. 7, No. 6. – P. 771-781.
- Loustaud-Ratti V., Rousseau A., Marquet P. Alain Ribavirin in chronic hepatitis C: past and future // Expert Review of Anti-infective Therapy. – 2009. – Vol. 7, No. 3. – P. 249-253.
- Suarez A., Redmond D. Desired Social Distance From People Who Have Hepatitis C Virus: An Exploration Among Staff in Health Care, Dentistry, Drug Treatment, and Tattoo / Body Piercing // Substance Use & Misuse. – 2014. – Vol. 49, No. 4. – P. 466-474.
- Toyoda H., Kumada T. Pharmacotherapy of chronic hepatitis C virus infection – the IDEAL trial: ‘2b or not 2b (= 2a), that is the question’ // Expert Opinion on Pharmacotherapy. – 2009. – Vol. 10, No. 17. – P. 2845-2857.